Assembly Biosciences Inc./$ASMB
13:30
14:25
15:15
16:10
17:00
1D1W1MYTD1Y5YMAX
About Assembly Biosciences Inc.
Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program.
Ticker
$ASMB
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
73
ISIN
US0453962070
Website
ASMB Metrics
BasicAdvanced
$140M
-
-$6.13
0.50
-
Price and volume
Market cap
$140M
Beta
0.5
52-week high
$18.92
52-week low
$7.75
Average daily volume
33K
Financial strength
Current ratio
2.049
Quick ratio
1.961
Long term debt to equity
9.181
Total debt to equity
11.13
Profitability
EBITDA (TTM)
-44.502
Gross margin (TTM)
-83.20%
Net profit margin (TTM)
-124.15%
Operating margin (TTM)
-138.81%
Effective tax rate (TTM)
-0.83%
Revenue per employee (TTM)
$440,000
Management effectiveness
Return on assets (TTM)
-25.49%
Return on equity (TTM)
-133.65%
Valuation
Price to revenue (TTM)
3.705
Price to book
5.14
Price to tangible book (TTM)
5.14
Price to free cash flow (TTM)
-2.12
Free cash flow yield (TTM)
-47.18%
Free cash flow per share (TTM)
-863.34%
Growth
Revenue change (TTM)
148.33%
Earnings per share change (TTM)
-41.67%
3-year revenue growth (CAGR)
72.59%
3-year earnings per share growth (CAGR)
-43.08%
10-year earnings per share growth (CAGR)
-16.48%
ASMB News
AllArticlesVideos
Assembly Biosciences Doses First Participant in Phase 1b Portion of Phase 1a/b Clinical Trial of Investigational Long-Acting Herpes Simplex Virus Helicase-Primase Inhibitor ABI-1179
GlobeNewsWire·4 days ago
Assembly Biosciences Reports Positive Topline Results from Phase 1b Clinical Trial of Next-Generation Investigational Capsid Assembly Modulator ABI-4334 in Chronic Hepatitis B
GlobeNewsWire·1 week ago
Assembly Biosciences to Present During the Jefferies 2025 Global Healthcare Conference
GlobeNewsWire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Assembly Biosciences Inc. stock?
Assembly Biosciences Inc. (ASMB) has a market cap of $140M as of July 04, 2025.
What is the P/E ratio for Assembly Biosciences Inc. stock?
The price to earnings (P/E) ratio for Assembly Biosciences Inc. (ASMB) stock is 0 as of July 04, 2025.
Does Assembly Biosciences Inc. stock pay dividends?
No, Assembly Biosciences Inc. (ASMB) stock does not pay dividends to its shareholders as of July 04, 2025.
When is the next Assembly Biosciences Inc. dividend payment date?
Assembly Biosciences Inc. (ASMB) stock does not pay dividends to its shareholders.
What is the beta indicator for Assembly Biosciences Inc.?
Assembly Biosciences Inc. (ASMB) has a beta rating of 0.5. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.